Cambridge, UK
o2h Ventures is pleased to announce its latest investment in Revolver Therapeutics, a University of Bath spin-out company. The company aims to transform pediatric cancer treatment through various approaches targeting childhood glioma.
Revolver Therapeutics is revolutionising cancer treatment by harnessing its ability to inhibit previously “undruggable” transcription factors. Transcription factors are proteins that help turn specific genes on or off by binding to nearby DNA in the cell nucleus and function as “master regulators” in cancer. The innovative TBS platform discovers peptides that functionally inhibit transcription factors inside cells to overcome the traditional hurdles faced by small molecules and antibodies.
o2h Ventures is investing in Revolver from the o2h human health SEIS fund along with co-investors including UK Innovation Science and Seed Fund (UKI2S), and Future Planet Capital. The company is initially targeting childhood gliomas, for which there is no effective treatment, in collaboration with the Institute of Cancer Research. With this investment, Revolver will explore applications for adult cancers in parallel.
The o2h human health SEIS fund seeks seis-eligible biotech companies to invest and support through our two specialist funds. To know more about the funds, please visit – https://o2hventures.com/funds
Sunil Shah, CEO of o2h Ventures, said:
We are thrilled to be supporting Revolver Tx; their work in transcription factor inhibition represents a significant advancement, particularly in targeting cancers that have been challenging to treat effectively. At o2h Ventures, we are dedicated to backing innovative science and an exceptional team with the potential for real impact, and we see Revolver’s platform as a world-class solution that aligns with our mission to support breakthroughs in human health
Jody Mason, CSO of Revolver and Professor of Biochemistry at the University of Bath, said:
Our breakthroughs are truly remarkable. We’ve achieved anti-tumour effects, while simultaneously solving the cellular penetration challenges that have hindered delivery of biologics in the past. We hope to make a significant impact in cancer treatment for childhood gliomas and beyond.
Professor Chris Jones, Professor of Childhood Brain Tumour Biology at The Institute of Cancer Research, London, said:
Paediatric gliomas have their origins in brain development, and many of the novel therapeutic targets we have discovered are transcription factors, which are normally switched off before birth, but remain switched on in the tumours themselves. Until now they have proven very difficult to drug, so it is exciting to be working with Revolver’s peptide technology to consider new ways to target these important molecules.
About Revolver Therapeutics
Revolver is revolutionising cancer treatment by harnessing its ability to inhibit previously “undruggable” transcription factors—proteins that help turn specific genes on or off by binding to nearby DNA in the cell nucleus and function as “master regulators” in cancer.
About o2h Ventures
The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in pre-seed and seed-stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tool offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7-acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com
